File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Anti-infective surgical therapy of peri-implantitis: a 12-month prospective clinical study
  • Basic View
  • Metadata View
  • XML View
TitleAnti-infective surgical therapy of peri-implantitis: a 12-month prospective clinical study
 
AuthorsHeitz-Mayfield, LJA2
Salvi, GE4
Mombelli, A3
Faddy, M5
Lang, NP1
 
Issue Date2012
 
PublisherWiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CLR
 
CitationClinical Oral Implants Research, 2012, v. 23 n. 2, p. 205-210 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1600-0501.2011.02276.x
 
AbstractAIM: The aim of this prospective cohort study was to evaluate an anti-infective surgical protocol for the treatment of peri-implantitis. MATERIALS AND METHODS: Thirty-six implants in 24 partially dentate patients with moderate to advanced peri-implantitis were treated using an anti-infective surgical protocol incorporating open flap debridement and implant surface decontamination, with adjunctive systemic amoxicillin and metronidazole. Treatment outcomes were assessed at 3, 6 and 12 months. Patient-based statistical analyses using multiple regression analyses were performed. RESULTS: There was 100% survival of treated implants at 12 months. At 3 months, there were statistically significant (P < 0.01) reductions in mean probing depths (PD), Bleeding on Probing (BoP) and suppuration. The greater the mean PD at baseline, the greater the PD reduction at 3 months. At 3 months, there was also a significant mean facial mucosal recession of 1 mm (P < 0.001). All these changes were maintained at 6 and 12 months. At 12 months, all treated implants had a mean PD < 5 mm, while 47% of the implants had complete resolution of inflammation (BoP negative). At 12 months, 92% of implants had stable crestal bone levels or bone gain. There were no significant effects of smoking on any of the treatment outcomes. CONCLUSIONS: For the treatment of peri-implantitis, an anti-infective protocol incorporating surgical access, implant surface decontamination and systemic antimicrobials followed by a strict postoperative protocol was effective at 3 months with the results maintained for up to 12 months after treatment.
 
DescriptionOn behalf of the Implant Complication Research Group
 
ISSN0905-7161
2012 Impact Factor: 3.433
2012 SCImago Journal Rankings: 1.154
 
DOIhttp://dx.doi.org/10.1111/j.1600-0501.2011.02276.x
 
ISI Accession Number IDWOS:000299098700010
Funding AgencyGrant Number
ITI Foundation for the Promotion of Implantology, Basel, Switzerland (ITI)341/04
Clinical Research Foundation (CRF) for The Promotion of Oral Health, Brienz, Switzerland (SKF/CRF)16/05
Funding Information:

This multicentre study was supported by a grant of the ITI Foundation for the Promotion of Implantology, Basel, Switzerland (ITI grant Nr. 341/04) and the Clinical Research Foundation (CRF) for The Promotion of Oral Health, Brienz, Switzerland (SKF/CRF grant Nr. 16/05.

 
DC FieldValue
dc.contributor.authorHeitz-Mayfield, LJA
 
dc.contributor.authorSalvi, GE
 
dc.contributor.authorMombelli, A
 
dc.contributor.authorFaddy, M
 
dc.contributor.authorLang, NP
 
dc.date.accessioned2012-02-28T01:52:59Z
 
dc.date.available2012-02-28T01:52:59Z
 
dc.date.issued2012
 
dc.description.abstractAIM: The aim of this prospective cohort study was to evaluate an anti-infective surgical protocol for the treatment of peri-implantitis. MATERIALS AND METHODS: Thirty-six implants in 24 partially dentate patients with moderate to advanced peri-implantitis were treated using an anti-infective surgical protocol incorporating open flap debridement and implant surface decontamination, with adjunctive systemic amoxicillin and metronidazole. Treatment outcomes were assessed at 3, 6 and 12 months. Patient-based statistical analyses using multiple regression analyses were performed. RESULTS: There was 100% survival of treated implants at 12 months. At 3 months, there were statistically significant (P < 0.01) reductions in mean probing depths (PD), Bleeding on Probing (BoP) and suppuration. The greater the mean PD at baseline, the greater the PD reduction at 3 months. At 3 months, there was also a significant mean facial mucosal recession of 1 mm (P < 0.001). All these changes were maintained at 6 and 12 months. At 12 months, all treated implants had a mean PD < 5 mm, while 47% of the implants had complete resolution of inflammation (BoP negative). At 12 months, 92% of implants had stable crestal bone levels or bone gain. There were no significant effects of smoking on any of the treatment outcomes. CONCLUSIONS: For the treatment of peri-implantitis, an anti-infective protocol incorporating surgical access, implant surface decontamination and systemic antimicrobials followed by a strict postoperative protocol was effective at 3 months with the results maintained for up to 12 months after treatment.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.descriptionOn behalf of the Implant Complication Research Group
 
dc.identifier.citationClinical Oral Implants Research, 2012, v. 23 n. 2, p. 205-210 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1600-0501.2011.02276.x
 
dc.identifier.doihttp://dx.doi.org/10.1111/j.1600-0501.2011.02276.x
 
dc.identifier.epage210
 
dc.identifier.hkuros198615
 
dc.identifier.isiWOS:000299098700010
Funding AgencyGrant Number
ITI Foundation for the Promotion of Implantology, Basel, Switzerland (ITI)341/04
Clinical Research Foundation (CRF) for The Promotion of Oral Health, Brienz, Switzerland (SKF/CRF)16/05
Funding Information:

This multicentre study was supported by a grant of the ITI Foundation for the Promotion of Implantology, Basel, Switzerland (ITI grant Nr. 341/04) and the Clinical Research Foundation (CRF) for The Promotion of Oral Health, Brienz, Switzerland (SKF/CRF grant Nr. 16/05.

 
dc.identifier.issn0905-7161
2012 Impact Factor: 3.433
2012 SCImago Journal Rankings: 1.154
 
dc.identifier.issue2
 
dc.identifier.pmid22092831
 
dc.identifier.scopuseid_2-s2.0-84855919545
 
dc.identifier.spage205
 
dc.identifier.urihttp://hdl.handle.net/10722/145507
 
dc.identifier.volume23
 
dc.languageeng
 
dc.publisherWiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CLR
 
dc.publisher.placeUnited States
 
dc.relation.ispartofClinical Oral Implants Research
 
dc.rightsThe definitive version is available at www3.interscience.wiley.com
 
dc.subject.meshAmoxicillin - therapeutic use
 
dc.subject.meshAnti-Bacterial Agents - therapeutic use
 
dc.subject.meshDebridement - methods
 
dc.subject.meshDecontamination - methods
 
dc.subject.meshPeri-Implantitis - surgery
 
dc.titleAnti-infective surgical therapy of peri-implantitis: a 12-month prospective clinical study
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Heitz-Mayfield, LJA</contributor.author>
<contributor.author>Salvi, GE</contributor.author>
<contributor.author>Mombelli, A</contributor.author>
<contributor.author>Faddy, M</contributor.author>
<contributor.author>Lang, NP</contributor.author>
<date.accessioned>2012-02-28T01:52:59Z</date.accessioned>
<date.available>2012-02-28T01:52:59Z</date.available>
<date.issued>2012</date.issued>
<identifier.citation>Clinical Oral Implants Research, 2012, v. 23 n. 2, p. 205-210</identifier.citation>
<identifier.issn>0905-7161</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/145507</identifier.uri>
<description>On behalf of the Implant Complication Research Group</description>
<description.abstract>AIM: The aim of this prospective cohort study was to evaluate an anti-infective surgical protocol for the treatment of peri-implantitis. MATERIALS AND METHODS: Thirty-six implants in 24 partially dentate patients with moderate to advanced peri-implantitis were treated using an anti-infective surgical protocol incorporating open flap debridement and implant surface decontamination, with adjunctive systemic amoxicillin and metronidazole. Treatment outcomes were assessed at 3, 6 and 12 months. Patient-based statistical analyses using multiple regression analyses were performed. RESULTS: There was 100% survival of treated implants at 12 months. At 3 months, there were statistically significant (P &lt; 0.01) reductions in mean probing depths (PD), Bleeding on Probing (BoP) and suppuration. The greater the mean PD at baseline, the greater the PD reduction at 3 months. At 3 months, there was also a significant mean facial mucosal recession of 1 mm (P &lt; 0.001). All these changes were maintained at 6 and 12 months. At 12 months, all treated implants had a mean PD &lt; 5 mm, while 47% of the implants had complete resolution of inflammation (BoP negative). At 12 months, 92% of implants had stable crestal bone levels or bone gain. There were no significant effects of smoking on any of the treatment outcomes. CONCLUSIONS: For the treatment of peri-implantitis, an anti-infective protocol incorporating surgical access, implant surface decontamination and systemic antimicrobials followed by a strict postoperative protocol was effective at 3 months with the results maintained for up to 12 months after treatment.</description.abstract>
<language>eng</language>
<publisher>Wiley-Blackwell Publishing, Inc.. The Journal&apos;s web site is located at http://www.blackwellpublishing.com/journals/CLR</publisher>
<relation.ispartof>Clinical Oral Implants Research</relation.ispartof>
<rights>The definitive version is available at www3.interscience.wiley.com</rights>
<subject.mesh>Amoxicillin - therapeutic use</subject.mesh>
<subject.mesh>Anti-Bacterial Agents - therapeutic use</subject.mesh>
<subject.mesh>Debridement - methods</subject.mesh>
<subject.mesh>Decontamination - methods</subject.mesh>
<subject.mesh>Peri-Implantitis - surgery</subject.mesh>
<title>Anti-infective surgical therapy of peri-implantitis: a 12-month prospective clinical study</title>
<type>Article</type>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1111/j.1600-0501.2011.02276.x</identifier.doi>
<identifier.pmid>22092831</identifier.pmid>
<identifier.scopus>eid_2-s2.0-84855919545</identifier.scopus>
<identifier.hkuros>198615</identifier.hkuros>
<identifier.volume>23</identifier.volume>
<identifier.issue>2</identifier.issue>
<identifier.spage>205</identifier.spage>
<identifier.epage>210</identifier.epage>
<identifier.isi>WOS:000299098700010</identifier.isi>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. University of Western Australia
  3. Université de Genève
  4. Universität Bern
  5. Queensland University of Technology